mitomycin has been researched along with Experimental Neoplasms in 153 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Three mouse cancer cell lines [CT26 mouse colon cancer cells, B16 melanoma cells and Lewis lung carcinoma (LLC)], 5 human carcinoma cell lines (human esophageal squamous cell carcinoma cell lines TE8 and HEC46 and the human pancreatic carcinoma cell lines PK-9, AsPC-1 and SUIT-2) and 5 chemotherapeutic agents [mitoxantrone (MIT), mitomycin C(MMC), 5-fluorouracil (5FU), camptothecin (CPT-11) and cisplatin (CDDP)] that are frequently used in a clinical setting for cancer treatment were utilized to investigate the surface expression level of calreticulin and HLA class I after exposure to chemotherapeutic agents." | 3.81 | The key role of calreticulin in immunomodulation induced by chemotherapeutic agents. ( Hirano, S; Kuroda, A; Kuwatani, T; Kyogoku, N; Maki, T; Miyauchi, K; Shichinohe, T; Takeuchi, S; Tsuchikawa, T; Wada, M; Yamamura, Y, 2015) |
| "The aim of this study was to determine the efficacy of epigallocatechin-3-gallate (EGCG) (Polyphenon E®) in comparison with mitomycin C (MMC) to prevent tumor cell implantation/growth in an animal model of superficial bladder cancer and search for possible mechanism(s) of action." | 3.80 | Epigallocatechin-3-gallate prevents tumor cell implantation/growth in an experimental rat bladder tumor model. ( Jankun, J; Keck, RW; Selman, SH, 2014) |
| " Nitrotriazole chemosensitizer in ultralow doses increased the sensitivity of leukemia P388/rn substrain with multiple drug resistance phenotype to mitomycin C during combination therapy." | 3.72 | Ultralow doses of various drugs in chemotherapy of experimental tumors. ( Konovalova, NP, 2003) |
| "Bestatin enhanced the antitumor effects of mitomycin C, 5-fluorouracil and cis-dichlorodiammineplatinum against a syngeneic solid tumor of colon adenocarcinoma 26 in BALB/c mice." | 3.67 | Enhancement of antitumor effect of cytotoxic agents by bestatin. ( Abe, F; Ashizawa, J; Horinishi, H; Ishizuka, M; Matsuda, A; Shibuya, K; Takahashi, K; Takeuchi, T; Umezawa, H, 1985) |
| " The technique of cauterization and implantation of tumor cells was performed in C3H/He mice to simulate the early stage of bladder cancer to evaluate a regimen of intravesical mitomycin C followed by the systemic immunopotentiator, levamisole." | 3.66 | Chemoimmunotherapy of implanted murine bladder cancer. ( Akaza, H; Crabtree, WN; Matheny, RB; Soloway, MS, 1983) |
| "We investigated the effectiveness of intravesically administered drugs on the tumor incidence and tumor size in a FANFT-induced animal model for bladder cancer." | 3.66 | Single and sequential combination intravesical chemotherapy of murine bladder cancer. ( McCallum, LW; Murphy, WM; Nissenkorn, I; Soloway, MS, 1982) |
| " Results of treatment of B16 melanoma and Lewis lung carcinoma with 3,4-dihydroxybenzohydroxamic acid are used to demonstrate this definition." | 3.66 | Drug activity and therapeutic synergism in cancer treatment. ( Campbell, ED; Carter, WH; Stablein, DM; Wampler, GL, 1982) |
| " Thus, we attempted to find the dose of a given drug that can reproduce in the nude mouse a plasma level similar to that seen in human patients treated with an effective dose of the drug based on comparative pharmacokinetic studies between man and nude mouse." | 2.66 | Pharmacokinetic approach to rational therapeutic doses for human tumor-bearing nude mice. ( Inaba, M; Kobayashi, T; Sakurai, Y; Tashiro, T, 1988) |
| "Hypoxic cells of solid tumors represent a therapeutically resistant population that limits the curability of many solid tumors by x-irradiation and by most chemotherapeutic agents." | 2.39 | Mitomycin C: a prototype bioreductive agent. ( Belcourt, MF; Fischer, JJ; Haffty, B; Hodnick, WF; Rockwell, S; Sartorelli, AC; Tomasz, M, 1994) |
| "Thirty‑six C57BL/6J mice bearing bladder cancer were randomly divided into six treatment groups as follows: control, BCG, MMC, ADM, MMC‑BCG and ADM‑BCG." | 1.51 | Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment. ( Fujimoto, K; Gotoh, D; Hori, S; Iida, K; Itami, Y; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, K; Onishi, S; Tanaka, N; Tatsumi, Y, 2019) |
| "Ninety mice bearing orthotopic bladder cancer induced by BBN were randomly divided into six groups and treated with chemotherapeutic agents once a week for four weeks." | 1.46 | Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model. ( Fujimoto, K; Hori, S; Miyake, M; Morizawa, Y; Nakai, Y; Onishi, S; Tanaka, N; Tatsumi, Y, 2017) |
| " Herein, we fabricated a safe delivery system of iPS cells treated with MMC loading with gold nanorods (AuNRs) for the targeted photothermal treatment of gastric cancer." | 1.46 | Mitomycin C-treated human-induced pluripotent stem cells as a safe delivery system of gold nanorods for targeted photothermal therapy of gastric cancer. ( Cui, D; Hou, W; Jiang, X; Liu, Y; Ni, J; Pan, F; Yang, M; Yang, Y; Zhang, C; Zhi, X, 2017) |
| "Human and murine colon cancer cell lines were subjected to mild hyperthermia (40-42°C), and treated with chemotherapy, similar to clinical protocols." | 1.38 | New insight into hyperthermic intraperitoneal chemotherapy: induction of oxidative stress dramatically enhanced tumor killing in in vitro and in vivo models. ( Clavien, PA; Gertsch, P; Graf, R; Humar, B; Jang, JH; Lehmann, K; Oberkofler, CE; Rickenbacher, A; von Boehmer, L; Vonlanthen, R, 2012) |
| " To explain this tumor selectivity, the distribution of FK317 was investigated after dosing tumor-bearing mice with the 14C-labelled compound." | 1.30 | FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice. ( Fujiwara, T; Inami, M; Kawamura, I; Manda, T; Matsumoto, S; Naoe, Y; Nishigaki, F; Shimomura, K; Takagaki, S; Tsujimoto, S; Yamazaki, S, 1998) |
| "5 mg/kg), or cisplatin (4 mg/kg, by one shot) to TNP (120-140 mg/kg) with a 6-7 fractionated dosing schedule reduced s." | 1.29 | Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice. ( Kakinuma, H; Kato, T; Matsuda, Y; Sato, K, 1994) |
| " When m-THPC PDT was combined with mitomycin C (MMC), light doses could be decreased by a factor of 2 for equal tumour effects." | 1.29 | Mechanisms for optimising photodynamic therapy: second-generation photosensitisers in combination with mitomycin C. ( Oppelaar, H; Oussoren, YG; Schuitmaker, JJ; Stewart, FA; van Geel, IP, 1995) |
| " On the other hand, the increase of the solid tumor weight in the every day treatment and in the every 7th day treatment of hEGF, in combination with the every 7th day administration of MMC, were as follows; from 282 +/- 41 mg to 1522 +/- 357 mg (71." | 1.28 | Response of A431 experimental human solid xenograft to mitomycin C in combination with human epidermal growth factor in mice. ( Amagase, H; Fuwa, T; Hashimoto, K; Murakami, T; Tamura, K; Yata, N, 1990) |
| "Augmentation of antitumor activity of Lactobacillus casei YIT 9018 (LC 9018), which strongly inhibits the growth of transplantable allogeneic and syngeneic mouse tumors, in combination with antitumor drugs was investigated." | 1.27 | [Augmentation of antitumor activity of Lactobacillus casei YIT 8018 (LC 9018) in combination with various antitumor drugs]. ( Kato, I; Matsuzaki, T; Mutai, M; Yokokura, T, 1984) |
| "Mitomycin C (MMC) has been evaluated in combination with several antitumor agents." | 1.27 | Mitomycin C combination therapy against murine tumor systems. Effectiveness with cyclophosphamide and methotrexate. ( Mabel, JA; Wodinsky, I, 1983) |
| "Moreover, malignant bladder tumors in rabbits were successfully treated with this method." | 1.27 | Intravesical chemotherapy of urinary bladder tumor in rabbit by ferromagnetic mitomycin C. ( Abe, R; Kato, T; Mori, H; Nemoto, R; Shindo, M, 1983) |
| "The effect of 5-fluorouracil (5-FU) in combination with herb medicine on the prolongation of survival rate in tumor bearing mice was studied." | 1.27 | [An approach to prolongation of survival rate in tumor bearing mice using 5-fluorouracil in combination with various kinds of herb medicine]. ( Abe, H; Odashima, S; Ohta, T; Tatsuka, M; Tawara, M, 1983) |
| "To study the feasibility of combined hyperthermic and anticancer drug treatment for peritoneal cancer, we devised a continuous hyperthermic peritoneal perfusion system in combination with mitomycin C." | 1.27 | Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. ( Hamazoe, R; Kanayama, H; Koga, S; Maeta, M; Osaki, Y; Shimizu, N, 1984) |
| " Both preparations provided a sustained-release property and a sensitive response to conventional magnetic force, although certain differences in the release rate of drug, magnetic responsiveness, and particle size were found between the two dosage forms." | 1.27 | Magnetic microcapsules for targeted delivery of anticancer drugs. ( Abe, R; Goto, A; Harada, M; Homma, M; Kato, T; Mori, H; Murota, H; Nemoto, R; Unno, K, 1984) |
| "Namely, most solid tumors possess four different unique features: hypervasculature, enhanced permeability even to macromolecules, architectural differences, and lack of the lymphatic recovery system." | 1.27 | [Tumor-targeted chemotherapy with lipid contrast medium and macro molecular anticancer agents theoretical considerations and clinical outcome]. ( Konno, T; Maeda, H, 1985) |
| "Hypoxic cells of solid tumors are relatively resistant to therapeutic assault." | 1.27 | Therapeutic attack of hypoxic cells of solid tumors: presidential address. ( Sartorelli, AC, 1988) |
| "In the amputation system of the same metastasis model at a dose of 4 mg/kg/d i." | 1.27 | A novel antitumor cyclic hexapeptide (RA-700) obtained from Rubiae radix. ( Hamanaka, T; Kawahara, K; Ohgoshi, M; Tsukagoshi, S; Tsuruo, T; Yamakawa, K, 1987) |
| "A new dosage form of activated carbon particles adsorbing mitomycin C (MMC-CH) was studied for its therapeutic effects on peritoneal dissemination in both animal experiments and preliminary clinical trials." | 1.27 | Intraoperative chemotherapy with carbon particles adsorbing mitomycin C for gastric cancer with peritoneal dissemination in rabbits. ( Hagiwara, A; Itoh, T; Lee, R; Takahashi, T; Takeda, M; Ueda, T, 1988) |
| " The serum level of M-83 detected by bioassay was biphasic, elimination half-life T1/2 beta was 10." | 1.27 | Antitumor activity and pharmacokinetics of 7-N-(p-hydroxyphenyl)mitomycin C in human tumor xenografts transplanted into nude mice. ( Asanuma, F, 1985) |
| "An aromatic retinoic acid analog (Ro 10-9359) was given orally in combination with intraperitoneal administration of mitomycin C (MMC), in an attempt to reduce the toxicity and enhance the therapeutic effect." | 1.26 | Therapeutic effect of an aromatic retinoic acid analog on rats with bladder carcinoma upon administration alone or in combination with mitomycin C. ( Fujita, J; Miyakawa, M; Tokuda, H; Yoshida, O, 1982) |
| "Mitomycin C was used as the chemotherapeutic agent and BCG as the immunopotentiating agent." | 1.26 | [Experimental study on local immunochemotherapy]. ( Fujita, Y; Imai, H; Kageyama, N; Kasuga, M; Majima, S; Sakita, M; Torii, T; Yamane, T, 1982) |
| "The effect of CDDP was studied on rat bladder tumors induced by N-butyl-N-(4-hydroxybutyl)-nitrosamine (BBN)." | 1.26 | [Effect of cis-diamminedichloroplatinum (II) (CDDP) on bladder cancer on rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)]. ( Miyakawa, M; Yoshida, O, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 107 (69.93) | 18.7374 |
| 1990's | 25 (16.34) | 18.2507 |
| 2000's | 10 (6.54) | 29.6817 |
| 2010's | 10 (6.54) | 24.3611 |
| 2020's | 1 (0.65) | 2.80 |
| Authors | Studies |
|---|---|
| Iyengar, BS | 2 |
| Sami, SM | 1 |
| Remers, WA | 2 |
| Bradner, WT | 3 |
| Schurig, JE | 2 |
| Lin, HJ | 1 |
| Cheng, L | 1 |
| Halder, AK | 1 |
| Adhikary, N | 1 |
| Maity, MK | 1 |
| Jha, T | 1 |
| Lin, S | 1 |
| Liang, Y | 1 |
| Cheng, J | 1 |
| Pan, F | 2 |
| Wang, Y | 1 |
| Hori, S | 2 |
| Miyake, M | 2 |
| Tatsumi, Y | 2 |
| Onishi, S | 2 |
| Morizawa, Y | 2 |
| Nakai, Y | 2 |
| Tanaka, N | 2 |
| Fujimoto, K | 3 |
| Onishi, K | 1 |
| Iida, K | 1 |
| Gotoh, D | 1 |
| Itami, Y | 1 |
| Jankun, J | 1 |
| Keck, RW | 1 |
| Selman, SH | 1 |
| Yamamura, Y | 2 |
| Tsuchikawa, T | 1 |
| Miyauchi, K | 1 |
| Takeuchi, S | 1 |
| Wada, M | 1 |
| Kuwatani, T | 1 |
| Kyogoku, N | 1 |
| Kuroda, A | 1 |
| Maki, T | 1 |
| Shichinohe, T | 1 |
| Hirano, S | 1 |
| Jia, M | 1 |
| Li, Y | 3 |
| Yang, X | 1 |
| Huang, Y | 2 |
| Wu, H | 2 |
| Lin, J | 2 |
| Hou, Z | 2 |
| Zhang, Q | 1 |
| Chang, Y | 1 |
| Yuan, C | 1 |
| Liu, C | 1 |
| Wang, S | 1 |
| Dai, L | 1 |
| Donin, NM | 1 |
| Duarte, S | 1 |
| Lenis, AT | 1 |
| Caliliw, R | 1 |
| Torres, C | 1 |
| Smithson, A | 1 |
| Strauss-Ayali, D | 1 |
| Agmon-Gerstein, Y | 1 |
| Malchi, N | 1 |
| Said, J | 1 |
| Raman, SS | 1 |
| Holden, S | 1 |
| Pantuck, A | 1 |
| Belldegrun, AS | 1 |
| Chamie, K | 1 |
| Yang, M | 1 |
| Liu, Y | 1 |
| Hou, W | 1 |
| Zhi, X | 1 |
| Zhang, C | 1 |
| Jiang, X | 1 |
| Yang, Y | 1 |
| Ni, J | 1 |
| Cui, D | 1 |
| Lehmann, K | 1 |
| Rickenbacher, A | 1 |
| Jang, JH | 1 |
| Oberkofler, CE | 1 |
| Vonlanthen, R | 1 |
| von Boehmer, L | 1 |
| Humar, B | 1 |
| Graf, R | 1 |
| Gertsch, P | 1 |
| Clavien, PA | 1 |
| Konovalova, NP | 1 |
| USUBUCH, I | 1 |
| OBOSHI, S | 1 |
| TSUCHIDA, R | 1 |
| TAZAWA, S | 1 |
| NARITA, N | 1 |
| TANABE, H | 1 |
| TAKAHASHI, F | 1 |
| MATSUMOTO, T | 2 |
| NARITA, K | 1 |
| SOKOLOFF, B | 3 |
| NAKABAYASHI, K | 1 |
| ENOMOTO, K | 2 |
| MILLER, TR | 1 |
| BICKNELL, A | 1 |
| BIRD, L | 2 |
| TRAUNER, W | 1 |
| NISWONGER, J | 1 |
| RENNINGER, G | 1 |
| TODA, Y | 1 |
| FUJISAWA, M | 1 |
| SAELHOF, CC | 1 |
| MILLER, C | 1 |
| KIMURA, Y | 1 |
| SUGIURA, K | 2 |
| MERKER, PC | 1 |
| TARNOWSKI, G | 1 |
| KULKA, P | 1 |
| BATES, L | 1 |
| SAFIER, S | 1 |
| SATTERWHITE, H | 1 |
| SOLNEY, E | 1 |
| THIELE, EH | 1 |
| ARISON, RN | 1 |
| BOXER, GE | 1 |
| BROCKMAN, RW | 2 |
| ANDERSON, EP | 1 |
| HANDLER, AH | 1 |
| SARRIS, TG | 1 |
| WILLS, C | 1 |
| KONDO, T | 1 |
| MCCONNELL, B | 1 |
| USUBUCHI, I | 1 |
| KAGEYAMA, T | 1 |
| UENO, K | 1 |
| KOIZUMI, A | 2 |
| YOSHIDA, K | 1 |
| TAKAHASHI, T | 2 |
| YAMAGUCHI, I | 1 |
| MAJIMA, S | 3 |
| STRAUB, PW | 1 |
| NELSON, JH | 1 |
| MARIK, LR | 1 |
| BURCHENAL, JH | 1 |
| HATTORI, T | 3 |
| ENDO, S | 1 |
| HAGIHARA, K | 1 |
| CLAPP, P | 1 |
| TAYAO, MS | 1 |
| TYREE, EB | 1 |
| NICKSON, JJ | 1 |
| CLARKSON, B | 1 |
| LAWRENCE, W | 1 |
| EVANS, JS | 1 |
| BOSTWICK, L | 1 |
| MENGEL, GD | 1 |
| HIRONO, I | 1 |
| KOJIMA, K | 1 |
| KACHI, H | 1 |
| OHASHI, A | 1 |
| SASAOKA, I | 1 |
| KOSHIURA, R | 1 |
| KOSHIMURA, S | 1 |
| BANDO, Y | 1 |
| SVEC, J | 1 |
| HUPKA, S | 1 |
| Peer, D | 1 |
| Dekel, Y | 1 |
| Melikhov, D | 1 |
| Margalit, R | 1 |
| Tian, M | 1 |
| Zhang, H | 1 |
| Higuchi, T | 1 |
| Oriuchi, N | 1 |
| Inoue, T | 2 |
| Endo, K | 2 |
| Pelz, JO | 1 |
| Doerfer, J | 1 |
| Hohenberger, W | 1 |
| Meyer, T | 1 |
| Obeid, M | 1 |
| Tesniere, A | 1 |
| Ghiringhelli, F | 1 |
| Fimia, GM | 1 |
| Apetoh, L | 1 |
| Perfettini, JL | 1 |
| Castedo, M | 1 |
| Mignot, G | 1 |
| Panaretakis, T | 1 |
| Casares, N | 1 |
| Métivier, D | 1 |
| Larochette, N | 1 |
| van Endert, P | 1 |
| Ciccosanti, F | 1 |
| Piacentini, M | 1 |
| Zitvogel, L | 1 |
| Kroemer, G | 1 |
| Clarke, C | 1 |
| Smyth, MJ | 1 |
| Aarts, F | 1 |
| Hendriks, T | 1 |
| Boerman, OC | 1 |
| Koppe, MJ | 1 |
| Oyen, WJ | 1 |
| Bleichrodt, RP | 1 |
| Hashida, M | 3 |
| Kato, A | 1 |
| Kojima, T | 1 |
| Muranishi, S | 1 |
| Sezaki, H | 3 |
| Tanigawa, N | 2 |
| Satomura, K | 1 |
| Hikasa, Y | 1 |
| Ono, Y | 1 |
| Kozai, Y | 1 |
| Ootsu, K | 1 |
| Imamishi, J | 1 |
| Tanaka, A | 1 |
| Matsuzaki, T | 1 |
| Kato, I | 1 |
| Yokokura, T | 1 |
| Mutai, M | 1 |
| Mitani, M | 2 |
| Iwano, K | 1 |
| Arika, T | 1 |
| Kikuchi, M | 1 |
| Ogura, T | 4 |
| Horie, K | 1 |
| Yamasaki, T | 1 |
| Nishimura, K | 1 |
| Tsuchiya, S | 1 |
| Yoshizawa, A | 1 |
| Akimoto, R | 1 |
| Watanabe, H | 1 |
| Shirasawa, K | 1 |
| Suzuki, M | 2 |
| Tsujimoto, Y | 1 |
| Fujita, J | 1 |
| Miyakawa, M | 2 |
| Tokuda, H | 1 |
| Yoshida, O | 2 |
| Mabel, JA | 1 |
| Wodinsky, I | 1 |
| Bottazzi, B | 1 |
| Polentarutti, N | 1 |
| Balsari, A | 1 |
| Boraschi, D | 1 |
| Ghezzi, P | 1 |
| Salmona, M | 1 |
| Mantovani, A | 1 |
| Akaza, H | 1 |
| Crabtree, WN | 1 |
| Matheny, RB | 1 |
| Soloway, MS | 3 |
| Kasuga, M | 2 |
| Sakita, M | 2 |
| Yamane, T | 2 |
| Torii, T | 2 |
| Tamai, M | 1 |
| Kageyama, N | 2 |
| Fujita, Y | 2 |
| Nemoto, R | 2 |
| Shindo, M | 1 |
| Mori, H | 2 |
| Abe, R | 2 |
| Kato, T | 3 |
| Tashiro, T | 3 |
| Fujimoto, S | 5 |
| Kobayashi, T | 5 |
| Inaba, M | 4 |
| Kasajima, T | 1 |
| Yamakawa, M | 1 |
| Maeda, K | 1 |
| Matsuda, M | 1 |
| Dobashi, M | 1 |
| Imai, Y | 1 |
| Endoh, F | 4 |
| Kitsukawa, Y | 3 |
| Morimoto, Y | 3 |
| Sugibayashi, K | 2 |
| Okui, K | 4 |
| Miyakawa, A | 1 |
| Suzuki, H | 1 |
| Spremulli, EN | 1 |
| Leith, JT | 2 |
| Bliven, SF | 2 |
| Campbell, DE | 1 |
| Dexter, DL | 1 |
| Glicksman, AS | 1 |
| Calabresi, P | 1 |
| Imai, R | 2 |
| Morimoto, M | 4 |
| Ohta, T | 1 |
| Tawara, M | 1 |
| Tatsuka, M | 1 |
| Abe, H | 1 |
| Odashima, S | 1 |
| Kataoka, T | 1 |
| Oh-hashi, F | 1 |
| Akabori, Y | 1 |
| Sakurai, Y | 4 |
| Okabe, M | 2 |
| Gomi, K | 2 |
| Ozaki, A | 1 |
| Saijo, N | 2 |
| Beppu, Y | 1 |
| Takahashi, K | 3 |
| Shimizu, E | 1 |
| Kimata, M | 1 |
| Hoshi, A | 1 |
| McCabe, RP | 1 |
| Evans, CH | 1 |
| Koga, S | 1 |
| Hamazoe, R | 1 |
| Maeta, M | 1 |
| Shimizu, N | 1 |
| Kanayama, H | 1 |
| Osaki, Y | 1 |
| Miyazaki, M | 2 |
| Shimura, T | 1 |
| Sugasawa, H | 1 |
| Takahashi, O | 1 |
| Kurihara, M | 1 |
| Kawata, S | 1 |
| Shreestha, RD | 1 |
| Kearney, R | 1 |
| Harrop, P | 1 |
| Rose, WC | 1 |
| Schlein, A | 1 |
| Huftalen, JB | 1 |
| Dennis, JW | 1 |
| Laferté, S | 1 |
| Man, MS | 1 |
| Elliott, BE | 1 |
| Kerbel, RS | 1 |
| Unno, K | 1 |
| Goto, A | 1 |
| Murota, H | 1 |
| Harada, M | 2 |
| Homma, M | 1 |
| Okubo, S | 1 |
| Tomita, F | 1 |
| Marumo, H | 2 |
| Nissenkorn, I | 1 |
| McCallum, LW | 1 |
| Murphy, WM | 1 |
| Tsuruo, T | 5 |
| Tsukagoshi, S | 2 |
| Mokyr, MB | 3 |
| Przepiorka, D | 1 |
| Dray, S | 3 |
| Chang, BK | 1 |
| Gutman, R | 1 |
| Carter, WH | 1 |
| Wampler, GL | 1 |
| Stablein, DM | 1 |
| Campbell, ED | 1 |
| Hopkins, SC | 1 |
| Matheny, R | 1 |
| Schmid, F | 1 |
| Otter, G | 1 |
| Stock, CC | 1 |
| Rübben, H | 1 |
| Dahm, HH | 1 |
| Lutzeyer, W | 1 |
| Nakatani, K | 1 |
| Miyagi, N | 1 |
| Ezaki, T | 1 |
| Shiratori, T | 1 |
| Takahashi, S | 1 |
| Konishi, Y | 1 |
| Yoshimoto, J | 1 |
| Shindo, H | 2 |
| Shinzato, O | 1 |
| Namba, M | 1 |
| Masuno, T | 2 |
| Kishimoto, S | 2 |
| Imai, H | 1 |
| Kubota, T | 1 |
| Hanatani, Y | 1 |
| Tsuyuki, K | 1 |
| Nakada, M | 1 |
| Asanuma, F | 2 |
| Ishibiki, K | 1 |
| Abe, O | 1 |
| Tsuru, S | 1 |
| Oguchi, M | 1 |
| Mashiko, M | 1 |
| Aiso, S | 1 |
| Zinnaka, Y | 1 |
| Nomoto, K | 3 |
| Yanai, S | 1 |
| Okada, H | 1 |
| Saito, K | 2 |
| Kuge, Y | 1 |
| Misaki, M | 1 |
| Ogawa, Y | 1 |
| Toguchi, H | 1 |
| Sato, K | 1 |
| Kakinuma, H | 1 |
| Matsuda, Y | 1 |
| Sartorelli, AC | 4 |
| Hodnick, WF | 1 |
| Belcourt, MF | 1 |
| Tomasz, M | 1 |
| Haffty, B | 1 |
| Fischer, JJ | 1 |
| Rockwell, S | 2 |
| van Geel, IP | 1 |
| Oppelaar, H | 2 |
| Oussoren, YG | 1 |
| Schuitmaker, JJ | 1 |
| Stewart, FA | 2 |
| Hara, K | 1 |
| Iwasaka, T | 1 |
| Matsuo, N | 1 |
| Nakao, Y | 1 |
| Yokoyama, M | 1 |
| Yamasaki, F | 1 |
| Mvula, M | 1 |
| Sugimori, H | 1 |
| Kamishohara, M | 2 |
| Kawai, H | 2 |
| Sakai, T | 1 |
| Isoe, T | 2 |
| Hasegawa, K | 1 |
| Mochizuki, J | 2 |
| Uchida, T | 2 |
| Kataoka, S | 1 |
| Yamaki, H | 1 |
| Odagawa, A | 1 |
| Hayakawa, Y | 1 |
| Seto, H | 1 |
| Otake, N | 1 |
| Durand, RE | 1 |
| LePard, NE | 1 |
| Baas, P | 1 |
| Michielsen, C | 1 |
| van Zandwijk, N | 1 |
| Akinaga, S | 1 |
| Nomura, K | 1 |
| Saeki, S | 1 |
| Nishiyama, M | 4 |
| Toge, T | 4 |
| Li, T | 1 |
| Tamada, K | 1 |
| Abe, K | 1 |
| Ito, O | 1 |
| Takenoyama, M | 1 |
| Jones, SN | 1 |
| Sands, AT | 1 |
| Hancock, AR | 1 |
| Vogel, H | 1 |
| Donehower, LA | 1 |
| Linke, SP | 1 |
| Wahl, GM | 1 |
| Bradley, A | 1 |
| Sakamoto, N | 1 |
| Naoe, Y | 2 |
| Inami, M | 2 |
| Matsumoto, S | 3 |
| Nishigaki, F | 2 |
| Tsujimoto, S | 2 |
| Kawamura, I | 2 |
| Miyayasu, K | 1 |
| Manda, T | 2 |
| Shimomura, K | 2 |
| Su, MY | 1 |
| Wang, Z | 1 |
| Nalcioglu, O | 1 |
| Takagaki, S | 1 |
| Fujiwara, T | 1 |
| Yamazaki, S | 1 |
| Hanaoka, K | 1 |
| Tanzawa, F | 1 |
| Tanaka, K | 1 |
| Shibayama, T | 1 |
| Miura, S | 1 |
| Ikeda, T | 1 |
| Iwabuchi, H | 1 |
| Nakagawa, A | 1 |
| Mitsuhashi, Y | 1 |
| Hisaoka, M | 1 |
| Kaneko, M | 1 |
| Tomida, A | 1 |
| Wataya, Y | 1 |
| Nomura, T | 2 |
| Sasaki, T | 1 |
| Matsuda, A | 2 |
| Kurakata, S | 1 |
| Hosokawa, M | 1 |
| Wexler, EJ | 1 |
| Gravallese, EM | 1 |
| Czerniak, PM | 1 |
| Devenny, JJ | 1 |
| Longtine, J | 1 |
| Wong, MK | 1 |
| Slee, AM | 1 |
| Kerr, JS | 1 |
| Phillips, RM | 1 |
| Burger, AM | 1 |
| Fiebig, HH | 1 |
| Double, JA | 1 |
| Masunaga, S | 1 |
| Ono, K | 2 |
| Abe, M | 1 |
| Ryoyama, K | 1 |
| Ryoyama, C | 1 |
| Nakamura, S | 2 |
| Kashimoto, S | 2 |
| Kajikawa, F | 1 |
| Nakata, K | 2 |
| Herman, TS | 2 |
| Teicher, BA | 2 |
| Holden, SA | 2 |
| Amagase, H | 1 |
| Tamura, K | 1 |
| Hashimoto, K | 1 |
| Fuwa, T | 1 |
| Murakami, T | 1 |
| Yata, N | 1 |
| Yamamoto, A | 1 |
| Takakura, Y | 2 |
| Oka, T | 1 |
| Furukawa-Furuya, M | 1 |
| Atsumi, R | 1 |
| Kakutani, T | 1 |
| Keyes, SR | 1 |
| Fujii, T | 1 |
| Sugita, N | 1 |
| Kobayashi, Y | 1 |
| Iijima, H | 1 |
| Matsunaga, K | 1 |
| Ando, T | 1 |
| Oguchi, Y | 1 |
| Morita, I | 1 |
| Yoshikumi, C | 1 |
| Ishikawa, S | 1 |
| Tachibana, T | 1 |
| Maeda, H | 2 |
| Konno, T | 1 |
| Noso, Y | 1 |
| Yamaguchi, M | 2 |
| Hirabayashi, N | 2 |
| Niimoto, M | 2 |
| Oikawa, T | 1 |
| Koga, Y | 1 |
| Tanahashi, K | 1 |
| Saito, T | 1 |
| Kobayashi, H | 1 |
| Kuzumaki, N | 1 |
| Shrieve, DC | 1 |
| Yoshida, H | 1 |
| Sohmura, Y | 1 |
| Taguchi, T | 1 |
| Matsumura, Y | 1 |
| Molla, A | 1 |
| Ishizeki, S | 1 |
| Ohtsuka, M | 1 |
| Irinoda, K | 1 |
| Kukita, K | 1 |
| Nagaoka, K | 1 |
| Nakashima, T | 1 |
| Nosoh, Y | 1 |
| Siemann, DW | 1 |
| Keng, PC | 1 |
| Hamanaka, T | 1 |
| Ohgoshi, M | 1 |
| Kawahara, K | 1 |
| Yamakawa, K | 1 |
| Faulkner, LE | 1 |
| Michelson, S | 1 |
| Maruo, K | 1 |
| Ohnishi, Y | 1 |
| Ueyama, Y | 1 |
| Hagiwara, A | 1 |
| Ueda, T | 1 |
| Lee, R | 1 |
| Takeda, M | 1 |
| Itoh, T | 1 |
| Fujiwara, H | 1 |
| Takai, Y | 1 |
| Fukuzawa, M | 1 |
| Yoshioka, T | 1 |
| Izumi, Y | 1 |
| Mizushima, Y | 1 |
| Qian, J | 1 |
| Ogata, M | 1 |
| Kosugi, A | 1 |
| Nakajima, H | 1 |
| Nelson, M | 1 |
| Nelson, DS | 1 |
| Colvin, M | 1 |
| Abe, F | 1 |
| Shibuya, K | 1 |
| Ashizawa, J | 1 |
| Horinishi, H | 1 |
| Ishizuka, M | 1 |
| Takeuchi, T | 1 |
| Umezawa, H | 1 |
| Gatanaga, T | 1 |
| Yamazaki, M | 1 |
| Mizuno, D | 1 |
| Abe, S | 1 |
| Sato, T | 1 |
| Hayashi, S | 1 |
| Bocian, RC | 1 |
| Ben-Efraim, S | 1 |
| Mori, K | 1 |
| Miake, S | 1 |
| Himeno, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of AMP-224, a PD-1 Inhibitor, in Combination With Stereotactic Body Radiation Therapy (SBRT) in Patients With Metastatic Colorectal Cancer[NCT02298946] | Phase 1 | 17 participants (Actual) | Interventional | 2014-11-21 | Completed | ||
| Immunogenicity and Safety of Autologous Dendritic Cells in Patients With Breast Cancer Treated With Neoadjuvant Chemotherapy.[NCT03450044] | Phase 1/Phase 2 | 15 participants (Actual) | Interventional | 2014-01-31 | Completed | ||
| Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer[NCT01440413] | 40 participants (Anticipated) | Interventional | 2011-12-31 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mandatory post treatment biopsies of the tumor were attempted on all patients. (NCT02298946)
Timeframe: Post treatment, day 29 +/- 7 days
| Intervention | Participants (Count of Participants) |
|---|---|
| DL1 - CTX, SBRTx1 Day, & AMP-224 | 6 |
| DL2 - CTX, SBRTx3 Days, and AMP-224 | 0 |
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. (NCT02298946)
Timeframe: Date treatment consent signed to date off study, approximately 24 months and 8 days
| Intervention | Participants (Count of Participants) |
|---|---|
| DL1 - CTX, SBRTx1 Day, & AMP-224 | 6 |
| DL2 - CTX, SBRTx3 Days, and AMP-224 | 9 |
Progression free survival is defined as the time interval from start of treatment to documented evidence of disease progression. Disease progression was evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and is at least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5mm. (Note: the appearance of one or more new lesions is also considered progressions). (NCT02298946)
Timeframe: Baseline to disease progression, an average of 2.6 months.
| Intervention | months (Median) |
|---|---|
| DL1 - CTX, SBRTx1 Day, & AMP-224 | 1.7 |
| DL2 - CTX, SBRTx3 Days, and AMP-224 | 2.7 |
"Objective response will be evaluated according to the revised Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 and is defined as Complete Response + Partial Response. Briefly, complete response (CR) is defined as the disappearance of all target lesions, and Partial Response is defined as at least 30% decrease in the sum of the diameters of the target lesions from baseline measurement." (NCT02298946)
Timeframe: Restaging was done every 8 weeks for an average of 2.6 months.
| Intervention | percentage of participants (Number) |
|---|---|
| DL1 - CTX, SBRTx1 Day, & AMP-224 | 0 |
| DL2 - CTX, SBRTx3 Days, and AMP-224 | 0 |
Overall survival is defined as the time from treatment start date until date of death or date last known alive. (NCT02298946)
Timeframe: Baseline to end of study, which is date of death. Average time participants were followed was 10.6 months.
| Intervention | months (Median) |
|---|---|
| DL1 - CTX, SBRTx1 Day, & AMP-224 | 4.3 |
| DL2 - CTX, SBRTx3 Days, and AMP-224 | 9.0 |
This outcome measure only represents the number of participants with metastatic colorectal cancer who had specimens collected for pre and post pharmacokinetic (PK) AMP-224 analyses. (NCT02298946)
Timeframe: Baseline and post infusion AMP-224 (e.g. 15 minutes after infusion ended)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Pre AMP-224 | Post AMP-224 | |
| DL1 - CTX, SBRTx1 Day, & AMP-224 | 6 | 6 |
| DL2 - CTX, SBRTx3 Days, and AMP-224 | 9 | 9 |
6 reviews available for mitomycin and Experimental Neoplasms
| Article | Year |
|---|---|
BIOCHEMISTRY OF CANCER (METABOLIC ASPECTS).
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Azaguanine; Azaserine; Carcinoma, Ehrlich Tum | 1963 |
MECHANISMS OF RESISTANCE TO ANTICANCER AGENTS.
Topics: Alkylating Agents; Antineoplastic Agents; Azaserine; Dactinomycin; DNA; Drug Resistance; Drug Resist | 1963 |
[Biological response modifying effect of chemotherapeutic agents against cancer].
Topics: Animals; Antineoplastic Agents; Cell Wall; Doxorubicin; Fluorouracil; Immunity, Cellular; Killer Cel | 1984 |
Mitomycin C: a prototype bioreductive agent.
Topics: Animals; Biotransformation; Cell Hypoxia; Clinical Trials as Topic; Combined Modality Therapy; Human | 1994 |
New chemotherapeutic agents for the treatment of non-small cell lung cancer: the Japanese experience.
Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phyto | 1998 |
[Possible clinical application of immunochemotherapy experimented in animals].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Bleo | 2000 |
2 trials available for mitomycin and Experimental Neoplasms
| Article | Year |
|---|---|
Pharmacokinetic approach to rational therapeutic doses for human tumor-bearing nude mice.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Cyclophosphamide; Doxorubicin; Drug Tolera | 1988 |
Responsiveness of human gastric tumors implanted in nude mice to clinically equivalent doses of various antitumor agents.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Mice; Mice, Inbred BALB C; Mice, N | 1988 |
145 other studies available for mitomycin and Experimental Neoplasms
| Article | Year |
|---|---|
Mitomycin C and porfiromycin analogues with substituted ethylamines at position 7.
Topics: Animals; Ethylamines; Female; Leukemia L1210; Leukemia P388; Leukopenia; Melanoma; Mice; Mitomycins; | 1983 |
Development of new mitomycin C and porfiromycin analogues.
Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Leukemia, Experimental; Melanoma; | 1981 |
Synthesis, pharmacological activity and comparative QSAR modeling of 1,5-N,N'-substituted-2-(substituted naphthalenesulphonyl) glutamamides as possible anticancer agents.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Cell Proliferation; Drug | 2010 |
Novel diaryl-2H-azirines: Antitumor hybrids for dual-targeting tubulin and DNA.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azirines; Cell Line, Tumor; Cell Proliferation; DNA; DNA | 2021 |
Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model.
Topics: Adjuvants, Immunologic; Administration, Intravesical; Animals; Antineoplastic Combined Chemotherapy | 2017 |
Intravesical treatment of chemotherapeutic agents sensitizes bacillus Calmette‑Guerin by the modulation of the tumor immune environment.
Topics: Administration, Intravesical; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; | 2019 |
Epigallocatechin-3-gallate prevents tumor cell implantation/growth in an experimental rat bladder tumor model.
Topics: Animals; Catechin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Female; | 2014 |
The key role of calreticulin in immunomodulation induced by chemotherapeutic agents.
Topics: Animals; Antigens, Surface; Antineoplastic Agents; Apoptosis; Calreticulin; Camptothecin; Carcinoma, | 2015 |
Development of both methotrexate and mitomycin C loaded PEGylated chitosan nanoparticles for targeted drug codelivery and synergistic anticancer effect.
Topics: Animals; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Chitosan; Drug Delivery Syste | 2014 |
Orthogonally functionalized nanoscale micelles for active targeted codelivery of methotrexate and mitomycin C with synergistic anticancer effect.
Topics: Animals; Antineoplastic Agents; Biopharmaceutics; Drug Carriers; Drug Delivery Systems; Drug Synergi | 2015 |
Sustained-release Formulation of Mitomycin C to the Upper Urinary Tract Using a Thermosensitive Polymer: A Preclinical Study.
Topics: Administration, Intravesical; Animals; Carcinoma, Transitional Cell; Cross-Linking Reagents; Delayed | 2017 |
Mitomycin C-treated human-induced pluripotent stem cells as a safe delivery system of gold nanorods for targeted photothermal therapy of gastric cancer.
Topics: Animals; Drug Delivery Systems; Female; Gold; Hot Temperature; Humans; Induced Pluripotent Stem Cell | 2017 |
New insight into hyperthermic intraperitoneal chemotherapy: induction of oxidative stress dramatically enhanced tumor killing in in vitro and in vivo models.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Chemotherapy, Cancer, Regional | 2012 |
Ultralow doses of various drugs in chemotherapy of experimental tumors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Resp | 2003 |
Inhibitory effect of mitomycin C upon experimental tumors.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agents; Humans; Mitomyci | 1957 |
Experimental studies on mitomycin C. I.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antitubercular; Dermatologic Agents; Mitomycin; Neoplas | 1959 |
Experimental studies on Mitomycin C. 4. Zymosan and the R. E. S.
Topics: Animals; Mitomycin; Mononuclear Phagocyte System; Neoplasms, Experimental; Zymosan | 1961 |
CYTOLOGICAL EFFECT OF CHEMICALS ON TUMORS. XVII. EFFECT OF MITOMYCIN-C AND CARZINOPHILIN ON HELA CELLS.
Topics: Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Antineoplastic Agents; Cell Biology; HeLa Ce | 1963 |
A MITOMYCIN C-RESISTANT JENSEN RAT SARCOMA: CHEMOTHERAPY STUDIES.
Topics: Animals; Antineoplastic Agents; Mitomycin; Mitomycins; Neoplasms; Neoplasms, Experimental; Pharmacol | 1963 |
EFFECTS OF CHEMICAL TREATMENT IN VITRO OF NELSON MOUSE ASCITES TUMOR CELLS ON THEIR TRANSPLANTABILITY AND ON SOME INDICES OF GLUCOSE METABOLISM.
Topics: Animals; Antineoplastic Agents; Ascites; Aziridines; Carbohydrate Metabolism; Carbon Isotopes; Carbo | 1963 |
ONCOLYSIS BY CLOSTRIDIA. III. EFFECTS OF CLOSTRIDIA AND CHEMOTHERAPEUTIC AGENTS ON RODENT TUMORS.
Topics: Adenocarcinoma; Animals; Antimetabolites; Antineoplastic Agents; Aziridines; Bacteriological Techniq | 1964 |
CHEMOTHERAPY STUDIES ON PRIMARY TUMOR GRAFTS AND METASTASES IN HAMSTERS AND MICE.
Topics: Antineoplastic Agents; Cricetinae; Cyclophosphamide; Dactinomycin; Melphalan; Mice; Mitomycin; Mitom | 1964 |
THE ADVERSE EFFECTS OF CANCER CHEMOTHERAPY.
Topics: Animals; Antineoplastic Agents; Azaguanine; Carcinoma, Ehrlich Tumor; Cortisone; Cyclophosphamide; D | 1964 |
HOST DEFENCE AND CHEMOTHERAPY IN EXPERIMENTAL CANCER.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Dactinomycin; Flavonoids; Lymphoma; Lymphoma, | 1964 |
ADMINISTRATION METHOD OF MITOMYCIN C.
Topics: Carcinoma, Hepatocellular; Liver Neoplasms; Methylcholanthrene; Mitomycin; Mitomycins; Neoplasms; Ne | 1964 |
PAPER ELECTROPHORETIC STUDIES ON SERUM PROTEINS IN THE DISEASES OF THE DIGESTIVE SYSTEM, WITH PARTICULAR REFERENCE TO THE CHANGES IN SERUM PROTEINS IN THE PATIENTS WITH CANCER.
Topics: Antineoplastic Agents; Blood Protein Electrophoresis; Blood Proteins; Carcinoma, Hepatocellular; Dig | 1963 |
[EXPERIMENTAL STUDIES ON THE PREVENTION OF HEMATOGENIC METASTASIS OF CANCER WITH ANTICANCER DRUGS].
Topics: Ascites; Blood Circulation; Injections, Intravenous; Liver Neoplasms; Mitomycin; Mitomycins; Neoplas | 1964 |
INHIBITORY EFFECT OF ANTI-CANCER CHEMOTHERAPEUTICS ON LIVER METASTASIS OF INTRAPORTALLY INOCULATED MOUSE ASCITES HEPATOMA.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; Injection | 1964 |
A TECHNIQUE FOR PROLONGED CONTINUOUS INTRA-ARTERIAL INFUSION IN RABBITS. METHOD FOR THE COMPARISON OF THE EFFECTS OF ANTICANCER DRUGS BY CONTINUOUS INTRA-ARTERIAL INFUSION IN THE RABBIT BEARING VX2 CARCINOMAS IN EACH HIND LIMB.
Topics: Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Femoral Artery; Gangrene; Infusions, Int | 1964 |
CYTOCIDAL EFFECTS OF MITOMYCIN-C ON MH-134 ASCITES TUMOR CELLS IN VITRO.
Topics: Animals; Ascites; Carcinoma, Ehrlich Tumor; In Vitro Techniques; Mice; Mitomycin; Mitomycins; Neopla | 1964 |
THE USE OF RAT ASCITES TUMORS HETEROGRAFTED IN MICE FOR SCREENING OF ANTICANCEROUS AGENTS.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Ascites; Carcinoma, Ehrlich Tumor; Carcinoma, | 1963 |
[EXPERIMENTAL STUDIES ON THE EFFECT OF ANTI-CANCER CHEMOTHERAPEUTICS TO LIVER METASTASIS FOLLOWING PORTAL INJECTION OF MOUSE ASCITES HEPATOMA].
Topics: Animals; Ascites; Carcinoma, Hepatocellular; Liver Neoplasms; Lung Neoplasms; Mice; Mitomycin; Mitom | 1963 |
AN EXPERIMENTAL STUDY OF SIMULTANEOUS IRRADIATION AND REGIONAL CHEMOTHERAPEUTIC PERFUSION.
Topics: Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Dactinomycin; Mitomycin; Mitomycins; Neo | 1964 |
SYNERGISM OF THE ANTINEOPLASTIC ACTIVITY OF CYTOSINE ARABINOSIDE BY PORFIROMYCIN.
Topics: Animals; Anti-Bacterial Agents; Antineoplastic Agents; Body Weight; Cytarabine; Cytosine; Leukemia; | 1964 |
[DEVELOPMENT OF FREE-CELL SUBLINES OF THE ASCITES HEPATOMA AH-130 AND THEIR BIOLOGICAL PROPERTIES].
Topics: Ascites; Carcinoma, Hepatocellular; Chromosomes; Electrons; Liver Neoplasms; Mechlorethamine; Micros | 1964 |
[EXPERIMENTAL ANTICANCER STUDIES. 23. FURTHER EXPERIMENTS ON THE ANTITUMOR ACTIVITY OF 4-AMINO-6-OCTYLRESORCINOL HYDROCHLORIDE].
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Carcinoma, Hepatocellular; Leukemia; Leuke | 1964 |
THE ACTION OF SOME CYTOSTATICS ON THE HEXOSE MONOPHOSPHATE SHUNT AND GLYCOLYSIS IN EXPERIMENTAL RAT TUMOURS.
Topics: Animals; Antineoplastic Agents; Carbohydrate Metabolism; Carbon Isotopes; Cytostatic Agents; Glucose | 1964 |
Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Lewis Lung; Cell Line, Tumor; Disease P | 2004 |
Effect of mitomycin C and vinblastine on FDG uptake of human nonsmall-cell lung cancer xenografts in nude mice.
Topics: Animals; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-R | 2004 |
A new survival model for hyperthermic intraperitoneal chemotherapy (HIPEC) in tumor-bearing rats in the treatment of peritoneal carcinomatosis.
Topics: Animals; Body Weight; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Drug; | 2005 |
Calreticulin exposure dictates the immunogenicity of cancer cell death.
Topics: Animals; Anthracyclines; Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Calreticulin; | 2007 |
Calreticulin exposure dictates the immunogenicity of cancer cell death.
Topics: Animals; Anthracyclines; Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Calreticulin; | 2007 |
Calreticulin exposure dictates the immunogenicity of cancer cell death.
Topics: Animals; Anthracyclines; Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Calreticulin; | 2007 |
Calreticulin exposure dictates the immunogenicity of cancer cell death.
Topics: Animals; Anthracyclines; Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Calreticulin; | 2007 |
Calreticulin exposure dictates the immunogenicity of cancer cell death.
Topics: Animals; Anthracyclines; Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Calreticulin; | 2007 |
Calreticulin exposure dictates the immunogenicity of cancer cell death.
Topics: Animals; Anthracyclines; Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Calreticulin; | 2007 |
Calreticulin exposure dictates the immunogenicity of cancer cell death.
Topics: Animals; Anthracyclines; Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Calreticulin; | 2007 |
Calreticulin exposure dictates the immunogenicity of cancer cell death.
Topics: Animals; Anthracyclines; Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Calreticulin; | 2007 |
Calreticulin exposure dictates the immunogenicity of cancer cell death.
Topics: Animals; Anthracyclines; Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Calreticulin; | 2007 |
Calreticulin exposure increases cancer immunogenicity.
Topics: Animals; Anthracyclines; Antigens, Differentiation; Antineoplastic Agents; Apoptosis; Calreticulin; | 2007 |
A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats.
Topics: Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Body Weight; Colonic Neoplasms; Combin | 2007 |
Antitumor activity of mitomycin C-dextran conjugate against various murine tumors.
Topics: Animals; Antineoplastic Agents; Carcinoma, Ehrlich Tumor; Dextrans; Female; Injections, Intravenous; | 1981 |
Antitumor and cytocidal activities of a newly isolated benzenoid ansamycin, macbecin I.
Topics: Animals; Antibiotics, Antineoplastic; Benzoquinones; Cell Line; Cell Survival; Chromomycin A3; DNA N | 1982 |
[Experimental research to clinical application of interferons].
Topics: Animals; Bleomycin; Cytarabine; Drug Therapy, Combination; Humans; Interferon Inducers; Interferon T | 1984 |
[Augmentation of antitumor activity of Lactobacillus casei YIT 8018 (LC 9018) in combination with various antitumor drugs].
Topics: Animals; Antineoplastic Agents; Bleomycin; Cyclophosphamide; Fluorouracil; Lacticaseibacillus casei; | 1984 |
[Experimental study on immunochemotherapy using schizophyllan].
Topics: Adjuvants, Immunologic; Animals; Glycosaminoglycans; Macrophage Activation; Male; Mammary Neoplasms, | 1982 |
[Anti-tumor activity of peripheral lymphocytes of tumor-bearing rats by in vitro culture].
Topics: Animals; Cells, Cultured; Female; Interleukin-2; Liver Neoplasms, Experimental; Lymphocyte Culture T | 1984 |
Therapeutic effect of an aromatic retinoic acid analog on rats with bladder carcinoma upon administration alone or in combination with mitomycin C.
Topics: Animals; Antineoplastic Agents; Carrier Proteins; Drug Therapy, Combination; Etretinate; Male; Mitom | 1982 |
Mitomycin C combination therapy against murine tumor systems. Effectiveness with cyclophosphamide and methotrexate.
Topics: Animals; Antibiotics, Antineoplastic; Cyclophosphamide; Doxorubicin; Drug Synergism; Drug Therapy, C | 1983 |
Chemotactic activity for mononuclear phagocytes of culture supernatants from murine and human tumor cells: evidence for a role in the regulation of the macrophage content of neoplastic tissues.
Topics: Animals; Cell Line; Cells, Cultured; Chemotactic Factors; Chemotaxis; Cycloheximide; Female; Humans; | 1983 |
Chemoimmunotherapy of implanted murine bladder cancer.
Topics: Animals; Carcinoma, Transitional Cell; Drug Therapy, Combination; Female; Levamisole; Mice; Mice, In | 1983 |
Intratumor chemoimmunotherapy with mitomycin C and BCG in C3H/He mice transplanted with MH134.
Topics: Animals; Antibody Formation; BCG Vaccine; Hypersensitivity, Delayed; Immunotherapy; Lymphatic Metast | 1983 |
Intravesical chemotherapy of urinary bladder tumor in rabbit by ferromagnetic mitomycin C.
Topics: Absorption; Animals; Ferric Compounds; Iron; Magnetics; Mitomycin; Mitomycins; Neoplasms, Experiment | 1983 |
[Experimental study on the evaluation of antineoplastic effects in the human cancer/nude mouse system].
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Cyclo | 1983 |
[Effect of cepharanthin on peripheral leukocytopenia caused by antineoplastic agents].
Topics: Alkaloids; Animals; Benzylisoquinolines; Fluorouracil; Leukopenia; Lymphoma; Mice; Mice, Inbred Stra | 1983 |
[Studies on biodegradable microspheres containing mitomycin C].
Topics: Animals; Biodegradation, Environmental; Microspheres; Mitomycin; Mitomycins; Neoplasm Transplantatio | 1983 |
Continued in vitro and in vivo release of an antitumor drug from albumin microspheres.
Topics: Animals; Antibiotics, Antineoplastic; Kinetics; Male; Microspheres; Mitomycin; Mitomycins; Neoplasms | 1983 |
Response of a human colon adenocarcinoma (DLD-1) to X irradiation and mitomycin C in vivo.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Colonic Neoplasms; Humans; Mice; Mice, Nude; M | 1983 |
Comparative antitumor activities of 7-N-(p-hydroxyphenyl)mitomycin C (M-83) and mitomycin C.
Topics: Animals; Antibiotics, Antineoplastic; HeLa Cells; Male; Mice; Mice, Inbred Strains; Mitomycin; Mitom | 1983 |
[An approach to prolongation of survival rate in tumor bearing mice using 5-fluorouracil in combination with various kinds of herb medicine].
Topics: Animals; Drug Therapy, Combination; Drugs, Chinese Herbal; Fluorouracil; Mice; Mitomycin; Mitomycins | 1983 |
Tumor dependency of concanavalin A-induced potentiation of tumor cell immunogenicity.
Topics: Animals; Antigens, Neoplasm; Concanavalin A; Dose-Response Relationship, Drug; Female; Glutaral; Mal | 1983 |
[Analysis of the mechanism of cancer metastasis by using anticancer agents].
Topics: Animals; Antineoplastic Agents; Cell Division; Cisplatin; Killer Cells, Natural; Liver Neoplasms; Ma | 1984 |
Secretion of proteinase inhibitors by tumorigenic and nontumorigenic guinea pig and Syrian hamster fibroblasts: evidence for autocrine regulation of local proteolysis.
Topics: Animals; Antibiotics, Antineoplastic; Cell Line; Chromatography, High Pressure Liquid; Cricetinae; F | 1984 |
Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug.
Topics: Animals; Antineoplastic Agents; Hyperthermia, Induced; Male; Mitomycin; Mitomycins; Neoplasms, Exper | 1984 |
[Preclinical studies of intra-arterial chemotherapy using mitomycin C microspheres].
Topics: Animals; Infusions, Intra-Arterial; Kinetics; Microspheres; Mitomycin; Mitomycins; Neoplasms, Experi | 1984 |
Intra-arterial administration of heated albumin microspheres containing mitomycin C to rabbits with VX-2 tumor.
Topics: Animals; Carcinoma; Cell Line; Delayed-Action Preparations; Infusions, Intra-Arterial; Kinetics; Mal | 1984 |
Modulation of anti-tumour immunity induced by syngeneic mitomycin C-treated murine tumour cells.
Topics: Animals; Antigens, Neoplasm; Cross Reactions; Female; Graft Rejection; Hypersensitivity, Delayed; Im | 1984 |
Antitumor activity and toxicity in animals of RR-150 (7-cysteaminomitosane), a new mitomycin derivative.
Topics: Animals; Antibiotics, Antineoplastic; Colonic Neoplasms; Drug Evaluation, Preclinical; Drug Resistan | 1984 |
Adoptive immune therapy in mice bearing poorly immunogenic metastases, using T lymphocytes stimulated in vitro against highly immunogenic mutant sublines.
Topics: Animals; Antibiotics, Antineoplastic; Immunization, Passive; Immunotherapy; Mice; Mice, Inbred DBA; | 1984 |
Magnetic microcapsules for targeted delivery of anticancer drugs.
Topics: Animals; Antineoplastic Agents; Aorta; Capsules; Cellulose; Dogs; Ferric Compounds; Magnetics; Mitom | 1984 |
Gilvocarcins, new antitumor antibiotics. 3. Antitumor activity.
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Coumarins; Glycosides; | 1981 |
Single and sequential combination intravesical chemotherapy of murine bladder cancer.
Topics: Animals; Antineoplastic Agents; Cisplatin; Disease Models, Animal; Doxorubicin; Drug Therapy, Combin | 1982 |
Antitumor activity of 7-n-(p-hydroxyphenyl)-mitomycin C in experimental tumor systems.
Topics: Animals; Carcinoma; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fibrosarcoma; Le | 1981 |
Mode of action of polyethylene glycol 6000 in potentiating the in vitro generation of antitumor cytotoxicity by MOPC-315 tumor bearer spleen cells.
Topics: Animals; Cells, Cultured; Cytotoxicity, Immunologic; Female; Immunization; Mice; Mice, Inbred BALB C | 1982 |
Chemotherapy of pancreatic adenocarcinoma: initial report on two transplantable models in the Syrian hamster.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cricetinae; Cyclophosphamide; Disease Models, Animal | 1982 |
Drug activity and therapeutic synergism in cancer treatment.
Topics: Animals; Antineoplastic Agents; Dacarbazine; Dose-Response Relationship, Drug; Drug Administration S | 1982 |
Systemic mitomycin C versus cisplatin: comparison of antitumor activity in primary murine bladder cancer.
Topics: Animals; Antibiotics, Antineoplastic; Cisplatin; Drug Synergism; FANFT; Female; Mice; Mitomycin; Mit | 1982 |
Effects of selected compounds on the McCall rat colon adenocarcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Azaserine; Colonic Neoplasms; Drug Therapy, Combinat | 1982 |
[Intravesical chemical prevention of recurrence. A randomized animal experimental study].
Topics: Administration, Topical; Animals; Cisplatin; Doxorubicin; Epithelium; Female; Mitomycin; Mitomycins; | 1982 |
[Heterotransplantation of human stomach carcinomas into nude nice. 3. Effects of MMC and 5FU on 7 strains of transplantable human gastric cancer in nude mice].
Topics: Animals; Fluorouracil; Humans; Male; Mice; Mice, Nude; Mitomycin; Mitomycins; Neoplasm Transplantati | 1982 |
[Study of in vitro sensitivity of human bladder cancer cell lines to sex steroid hormones. Combined effects of adriamycin or mitomycin-C and estradiol-17 beta on T24 cells].
Topics: Cell Line; Cell Survival; Doxorubicin; Drug Synergism; Estradiol; Humans; Mitomycin; Mitomycins; Neo | 1982 |
In vitro tumor cell killing by peritoneal macrophages from mitomycin C-treated rats.
Topics: Animals; Antibiotics, Antineoplastic; Cell Adhesion; Cytotoxicity, Immunologic; Deoxyglucose; Fibros | 1982 |
[Experimental study on local immunochemotherapy].
Topics: Animals; Antibiotics, Antineoplastic; BCG Vaccine; Hemolytic Plaque Technique; Hypersensitivity, Del | 1982 |
[Effect of cis-diamminedichloroplatinum (II) (CDDP) on bladder cancer on rats induced by N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN)].
Topics: Animals; Butylhydroxybutylnitrosamine; Cisplatin; Cyclophosphamide; Female; Mitomycin; Mitomycins; N | 1982 |
[Effect of mitomycin C on human gastric and colon carcinomas serially transplanted to nude mice--with special reference to the start of drug administration].
Topics: Animals; Cell Division; Colonic Neoplasms; Humans; Mice; Mice, Nude; Mitomycin; Mitomycins; Neoplasm | 1982 |
[Effect of PSK on tumor-specific immunity induced by MMC-treated syngeneic tumor cells].
Topics: Animals; Antibiotics, Antineoplastic; Cytotoxicity, Immunologic; Female; Immunization; Killer Cells, | 1982 |
Antitumor effect of arterial administration of a medium-chain triglyceride solution of an angiogenesis inhibitor, TNP-470, in rabbits bearing VX-2 carcinoma.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Caprylates; Ca | 1995 |
Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; C | 1994 |
Mechanisms for optimising photodynamic therapy: second-generation photosensitisers in combination with mitomycin C.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cell | 1995 |
Effects of single and combined application of anti-cancer drugs on cervical adenocarcinoma. I. Antitumor activity in vitro.
Topics: Adenocarcinoma; Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line; Combined | 1995 |
Antitumor activity of a spicamycin derivative, KRN5500, and its active metabolite in tumor cells.
Topics: Animals; Antineoplastic Agents; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Mice, I | 1994 |
Antitumor activity of SPM VIII, a derivative of the nucleoside antibiotic spicamycin, against human tumor xenografts.
Topics: Animals; Antibiotics, Antineoplastic; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mitomyc | 1994 |
Modulation of tumor hypoxia by conventional chemotherapeutic agents.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Doxorubicin; Humans; Mice; Mice, Inbred C3H; Mitomycin | 1994 |
Enhancement of interstitial photodynamic therapy by mitomycin C and EO9 in a mouse tumour model.
Topics: Animals; Antineoplastic Agents; Aziridines; Combined Modality Therapy; Drug Screening Assays, Antitu | 1994 |
Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C.
Topics: Alkaloids; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Division; Drug | 1993 |
DT-diaphorase as a target enzyme for biochemical modulation of mitomycin C.
Topics: Animals; Antibiotics, Antineoplastic; Biotransformation; DNA Damage; Enzyme Inhibitors; Humans; Hydr | 1995 |
The antitumor effect induced by local injections with interleukin-2 is diminished by combing with a local injection with mitomycin C.
Topics: Animals; Drug Administration Routes; Drug Therapy, Combination; Female; Fibrosarcoma; Interleukin-2; | 1996 |
The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2.
Topics: Animals; Cell Cycle; Cell Division; Cell Transformation, Neoplastic; Cells, Cultured; Crosses, Genet | 1996 |
Tumor-specific synergistic therapy of mitomycin C: modulation of bioreductive activation.
Topics: 3-Iodobenzylguanidine; Animals; Antibiotics, Antineoplastic; Biotransformation; Cell Division; Dicum | 1997 |
FK317: a novel substituted dihydrobenzoxazine with potent antitumor activity which does not induce vascular leak syndrome.
Topics: Animals; Antineoplastic Agents; Capillary Leak Syndrome; Drug Screening Assays, Antitumor; Female; M | 1998 |
Investigation of longitudinal vascular changes in control and chemotherapy-treated tumors to serve as therapeutic efficacy predictors.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Capillary Permeability; Contrast Media; Female | 1999 |
FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biotransformation; Body Weight; Carcinoma, Large Cel | 1998 |
Antitumor activity and novel DNA-self-strand-breaking mechanism of CNDAC (1-(2-C-cyano-2-deoxy-beta-D-arabino-pentofuranosyl) cytosine) and its N4-palmitoyl derivative (CS-682).
Topics: Administration, Oral; Animals; Antimetabolites, Antineoplastic; Arabinonucleosides; Biotransformatio | 1999 |
Tumor biology: use of tiled images in conjunction with measurements of cellular proliferation and death in response to drug treatments.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycl | 2000 |
Genotyping of NAD(P)H:quinone oxidoreductase (NQO1) in a panel of human tumor xenografts: relationship between genotype status, NQO1 activity and the response of xenografts to Mitomycin C chemotherapy in vivo(1).
Topics: Animals; Antibiotics, Antineoplastic; Disease Models, Animal; FMN Reductase; Genotype; Humans; Mice; | 2001 |
Potentially lethal damage repair by quiescent cells in murine solid tumors.
Topics: Animals; Cell Survival; DNA Repair; DNA, Neoplasm; Female; Mice; Mice, Inbred C3H; Micronucleus Test | 1992 |
Cyclophosphamide modifies the induction kinetics but not cell types and cytotoxic mechanisms of antitumor cells elicited with OK-432 plus attenuated tumor cells.
Topics: Animals; Arachidonic Acid; Cell Cycle; Cell Division; Cyclophosphamide; Exudates and Transudates; Ki | 1991 |
Combination effect of recombinant human interleukin 1 alpha with antitumor drugs on syngeneic tumors in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Col | 1991 |
Trimodality therapy (drug/hyperthermia/radiation) with BCNU or mitomycin C.
Topics: Animals; Carmustine; Cell Line; Cesium Radioisotopes; Combined Modality Therapy; Hyperthermia, Induc | 1990 |
Addition of a hypoxic cell selective cytotoxic agent (mitomycin C or porfiromycin) to Fluosol-DA/carbogen/radiation.
Topics: Animals; Carbon Dioxide; Cell Hypoxia; Dose-Response Relationship, Radiation; Drug Combinations; Flu | 1990 |
Response of A431 experimental human solid xenograft to mitomycin C in combination with human epidermal growth factor in mice.
Topics: Animals; Antineoplastic Agents; Body Weight; Drug Administration Schedule; Drug Therapy, Combination | 1990 |
The role of mitomycin antibiotics in the chemotherapy of solid tumors.
Topics: Anaerobiosis; Animals; Biotransformation; Cytochromes; Dicumarol; Drug Synergism; Female; Mammary Ne | 1986 |
Cellular interaction and in vitro antitumor activity of mitomycin C-dextran conjugate.
Topics: Adsorption; Animals; Biological Transport; Cell Compartmentation; Cell Cycle; Cell Membrane; Culture | 1986 |
Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Topics: Animals; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line; Cisplatin; DNA; Dose-Response Rel | 1987 |
[Effects of anti-tumor drugs on thermosensitivity of thermotolerant cells and thermotolerance development].
Topics: Animals; Bleomycin; Cell Survival; Cells, Cultured; Combined Modality Therapy; Cricetinae; Cricetulu | 1986 |
Disposition characteristics of mitomycin C-dextran conjugate in normal and tumor-bearing muscles of rabbits.
Topics: Animals; Dextrans; Male; Mitomycin; Mitomycins; Muscles; Neoplasms, Experimental; Rabbits; Serum Alb | 1987 |
Modulation of the antineoplastic efficacy of mitomycin C by dicoumarol in vivo.
Topics: Animals; Cell Survival; Dicumarol; Drug Interactions; Hematopoietic Stem Cells; Mice; Mice, Inbred B | 1989 |
Treatment with Krestin combined with mitomycin C, and effect on immune response.
Topics: Animals; Antibody Formation; Antineoplastic Combined Chemotherapy Protocols; Female; Hypersensitivit | 1989 |
Killer-helper effect of L cells in the generation of anti-MM cytotoxic T lymphocytes: replacement by beta-interferon and mechanisms of action.
Topics: Animals; Antibodies; Antigens, Neoplasm; Cell Adhesion; Complement System Proteins; Cytotoxicity, Im | 1986 |
[Tumor-targeted chemotherapy with lipid contrast medium and macro molecular anticancer agents theoretical considerations and clinical outcome].
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Biological Availability; Capillary Perm | 1985 |
[Sensitivity test of anticancer agents by subrenal capsule assay (SRC assay). II--Determination of tumor sensitivity by percentage inhibition of DNA protein].
Topics: Animals; Antineoplastic Agents; Colony-Forming Units Assay; Cyclophosphamide; DNA, Neoplasm; Fluorou | 1986 |
[Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice and rats].
Topics: Animals; Concanavalin A; Dose-Response Relationship, Drug; Fibrosarcoma; Injections; Lymphokines; Ma | 1986 |
Genetic background of high incidence of spontaneous tumors in BDX rats.
Topics: Animals; Aryl Hydrocarbon Hydroxylases; Cell Transformation, Neoplastic; Killer Cells, Natural; Meth | 1986 |
Enhancement of EMT6/SF tumor cell killing by mitomycin C and cyclophosphamide following in vivo administration of buthionine sulfoximine.
Topics: Animals; Buthionine Sulfoximine; Cyclophosphamide; Drug Synergism; Glutathione; Male; Methionine Sul | 1986 |
[Combined effect of PT-050 (recombinant human TNF) and antitumor drugs on syngeneic murine tumors].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cisplatin; Colonic Neoplasms; Cyclophosphamide; Doxo | 1986 |
Antitumor activity of some bacterial proteases: eradication of solid tumors in mice by intratumor injection.
Topics: Animals; Ascites; Mice; Mitomycin; Mitomycins; Neoplasms, Experimental; Peptide Hydrolases; Protease | 1987 |
Azinomycins A and B, new antitumor antibiotics. III. Antitumor activity.
Topics: Animals; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Azabicyclo Compounds; Carcinoma, Ehrlic | 1987 |
Comparative study on nude mice isotope assay (NM-IA) and subrenal capsule assay (SRCA) sensitivity tests of anticancer agents.
Topics: Animals; Antineoplastic Agents; Cisplatin; Colony-Forming Units Assay; Cyclophosphamide; Doxorubicin | 1987 |
Therapeutic attack of hypoxic cells of solid tumors: presidential address.
Topics: Animals; Humans; Hypoxia; Mitomycin; Mitomycins; Neoplasms; Neoplasms, Experimental | 1988 |
Responses of tumor cell subpopulations to single modality and combined modality therapies.
Topics: Animals; Antineoplastic Agents; Cell Survival; Combined Modality Therapy; Cyclophosphamide; Lomustin | 1988 |
A novel antitumor cyclic hexapeptide (RA-700) obtained from Rubiae radix.
Topics: Animals; Antineoplastic Agents, Phytogenic; Doxorubicin; Drug Evaluation, Preclinical; Female; Leuke | 1987 |
Compositional stability of artificial heterogeneous tumors in vivo: use of mitomycin C as a cytotoxic probe.
Topics: Animals; Cell Division; Cell Survival; Humans; Mice; Mitomycin; Mitomycins; Neoplasm Transplantation | 1988 |
Intraoperative chemotherapy with carbon particles adsorbing mitomycin C for gastric cancer with peritoneal dissemination in rabbits.
Topics: Adsorption; Adult; Aged; Animals; Antineoplastic Agents; Carbon; Female; Humans; Intraoperative Peri | 1988 |
[The augmentation of tumor-specific immunity by T-T cell interaction].
Topics: Animals; Antigens, Neoplasm; BCG Vaccine; Cell Communication; Cross Reactions; Haptens; Histocompati | 1985 |
Stimulation of proliferation in mixed cultures of mouse tumor cells and nonimmune peritoneal cells. II. Stimulation of tumor cells by macrophages and of lymphocytes by a tumor cell product.
Topics: Animals; Ascitic Fluid; Autoradiography; Cell Communication; Cell Division; Cell Survival; Cells, Cu | 1985 |
Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.
Topics: Adjuvants, Immunologic; Animals; Cyclophosphamide; Cytotoxicity, Immunologic; Female; Immune Toleran | 1985 |
Enhancement of antitumor effect of cytotoxic agents by bestatin.
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cisplatin; Colonic Neop | 1985 |
Combination antitumor therapy with rabbit tumor necrosis factor and chemo- and immuno-therapeutic agents against murine tumors.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dactinomycin; Doxorubicin; Glycoproteins; | 1985 |
[Tissue concentration of MMC by intra-arterial chemotherapy. Experimental study].
Topics: Animals; Injections, Intra-Arterial; Mitomycin; Mitomycins; Neoplasms, Experimental; Rats; Rats, Inb | 1985 |
Induction of activated macrophages by intraperitoneal injection of mitomycin C in mice.
Topics: Animals; Antineoplastic Agents; Cytotoxicity, Immunologic; Dose-Response Relationship, Drug; Injecti | 1985 |
Melphalan-induced enhancement of tumor cell immunostimulatory capacity as a mechanism for the appearance of potent antitumor immunity in the spleen of mice bearing a large metastatic MOPC-315 tumor.
Topics: Animals; Cell Division; Cytotoxicity, Immunologic; Immunity, Cellular; Melphalan; Mice; Mitomycin; M | 1985 |
Rejection of syngeneic tumor cells by the interaction of Lyt-1+ T lymphocytes and macrophages.
Topics: Animals; Antibody-Dependent Cell Cytotoxicity; Antigens, Ly; Graft Rejection; Isoantibodies; Macroph | 1985 |
Antitumor activity and pharmacokinetics of 7-N-(p-hydroxyphenyl)mitomycin C in human tumor xenografts transplanted into nude mice.
Topics: Animals; Antibiotics, Antineoplastic; Autoradiography; Humans; Kidney; Kinetics; Liver; Male; Mice; | 1985 |